LIPO

3.79% -0.0186

Handel nachbörslich: .46 -0.012 -2.54%

Lipella Pharmaceuticals Inc (LIPO)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Lipella Pharmaceuticals Inc

412-901-0315

400 N LEXINGTON ST, PITTSBURGH

Nächster Verdiensttermin

Neueste SEC-Einreichungen

LIPO's Discussions on Twitter

Lipella Pharmaceuticals Inc Aktie (LIPO) Neueste Nachrichten

Finanzdaten der Lipella Pharmaceuticals Inc-Aktie (LIPO)

Lipella Pharmaceuticals Inc (LIPO)

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Lipella Pharmaceuticals Inc Aktie (LIPO) Neueste Nachrichten

Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily

Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily

The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News

Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar

Lipella reports positive phase 2a trial results for OLP treatment - Investing.com

Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan

A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News

Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex

Lipella stock soars 200% on Phase 2 study initiation - MSN

Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga

Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World

John Deneen Collins Sells 85,126 Shares of LivePerson, Inc. (NASDAQ:LPSN) Stock - Defense World

Lepidico Wins Crucial Road Access Dispute - TipRanks

Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada

LivePerson CFO and COO sells over $89k in company stock - Investing.com

Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat

A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News

Moody’s to withdraw Lippo Malls Indonesia Retail Trust’s credit ratings - The Edge Singapore

UK Government gets behind Lepidico’s process technologies - Mining.com.au

Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat

Understanding the Risks of Investing in Lipella Pharmaceuticals Inc (LIPO) - Knox Daily

Stock Surge: Lipella Pharmaceuticals Inc (LIPO) Closes at 0.40, Marking a 6.96 Increase/Decrease - The Dwinnex

A closer look at LIPO’s price-to-free cash flow ratio - US Post News

Interstitial Cystitis Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation - Barchart

Lipella Pharmaceuticals announces board election and reverse stock split - Investing.com

Lipella Pharmaceuticals Inc [LIPO] Investment Guide: What You Need to Know - Knox Daily

Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - MSN

A Guide To The Risks Of Investing In Lipella Pharmaceuticals Inc (LIPO) - Knox Daily

LIPO’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

LIPOLipella Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York - GlobeNewswire

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York - StockTitan

Investing in Lipella Pharmaceuticals Inc (LIPO): What You Must Know - Knox Daily

Lipella Pharmaceuticals Inc (LIPO) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com

Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Lipella Pharmaceuticals Inc [LIPO] moved up 1.71: Why It’s Important - The DBT News

Ratio Revelations: Lipella Pharmaceuticals Inc (LIPO)’s Financial Metrics in the Spotlight - The Dwinnex

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research - GlobeNewswire

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research - StockTitan

Lipella Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily

Lipella Pharmaceuticals Inc (LIPO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference - GlobeNewswire

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference - StockTitan

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference - Yahoo Finance

Financial Review: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023) - Simply Wall St

Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023) - Yahoo Finance

Finanzdaten der Lipella Pharmaceuticals Inc-Aktie (LIPO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie LIPO